Bausch Health Companies INC

Michael Goettler has resigned from the Bausch Health Companies Inc. Board of Directors, effective June 30, 2026, to become President and CEO of Knoa Pharma LLC.

Bausch Health Companies Inc. held its Annual Meeting of Shareholders on May 19, 2026, where shareholders elected directors, approved executive compensation on an advisory basis, and appointed PricewaterhouseCoopers LLP as auditors.

Bausch Health Companies Inc. announced it will settle 2023 performance share unit awards for executives Thomas Appio and Seana Carson in cash rather than stock upon their vesting on March 3, 2026.

Bausch Health announced its global Phase 3 RED-C clinical program for amorphous-rifaximin SSD in hepatic encephalopathy did not meet its primary endpoint.

Bausch Health Companies Inc. announced it will reaffirm its full year 2025 guidance at the higher end of the range during the upcoming J.P. Morgan Healthcare Conference.

Bausch + Lomb Corporation completed a credit agreement refinancing, securing $2.8 billion in new term B loans with reduced interest margins and an extended maturity for a portion of its debt.

Bausch Health Companies Inc. reported a 13% increase in Q2 2026 revenue to $2.85 billion, driven by pricing and acquisitions, but a significant goodwill impairment led to a net loss attributable to the company of $1.17 billion for the six-month period.

Bausch Health reports strong Q3 2025 revenue growth of 7% to $2.681 billion, driven by Bausch + Lomb, Salix, and Solta Medical segments, alongside significant debt refinancing activities.

Bausch Health Companies Inc. reported a significant turnaround to net income in Q2 2025, driven by revenue growth and successful debt refinancing efforts, despite rising interest expenses and ongoing legal challenges.

Bausch Health Companies Inc. announces its Q1 2025 financial results, highlights debt refinancing efforts, and addresses ongoing legal proceedings, including Xifaxan patent litigation.

Bausch Health Companies Inc. saw a revenue increase in Q3 2024, while also managing to reduce its net losses compared to the same period last year.

Bausch Health Companies Inc. reports an 11% increase in revenue for the second quarter of 2024, driven by growth across all segments.

Bausch Health Companies Inc. reports a revenue increase of 10% in 2024, driven by growth across all segments and strategic focus on core therapeutic areas.

Bausch Health Companies Inc. released its 2023 annual report, highlighting financial performance across its segments and strategic initiatives including the potential separation of Bausch + Lomb.

Aimee J. Lenar, President, US Pharma of Bausch Health Companies Inc., reported a transaction in 5,260 shares of common stock on July 17, 2026.

Aimee J. Lenar, President, US Pharma of Bausch Health Companies Inc., reported a transaction in 23,395 shares of common stock on July 15, 2026.

Steven Hyosig Lee, SVP, Controller & CAO of Bausch Health Companies Inc., reported a transaction in 3,125 shares of common stock on July 14, 2026.

Amy B. Wechsler, a Director at Bausch Health Companies Inc., acquired 1,394 common shares through Restricted Share Units.

John Paulson, a director at Bausch Health Companies Inc., acquired 12,677 common shares through restricted stock units.

Amy B. Wechsler, a Director at Bausch Health Companies Inc., was granted restricted stock units valued at $250,000.

Bausch Health Companies Inc. has announced its 2026 Annual Meeting of Shareholders will be held virtually on May 19, 2026, to elect directors, approve executive compensation, and appoint auditors.

Bausch Health Companies Inc. calls a Special Meeting for October 7, 2025, to ratify its recently adopted shareholder rights plan, aimed at ensuring fair treatment for all shareholders in potential take-over bids.

Bausch Health Companies Inc. updates its proxy statement with revised information regarding the beneficial ownership of its common shares by Carl Icahn and Paulson & Co., Inc. in preparation for the 2025 Annual Meeting of Shareholders.

Bausch Health Companies Inc. has filed a definitive proxy statement with the SEC, soliciting material pursuant to Section 240.14a-12.

Bausch Health Companies Inc. announces its 2025 Annual Meeting of Shareholders to be held virtually on May 13, 2025, featuring proposals for director elections, executive compensation, and employee stock purchase plan approval.

Bausch Health Companies Inc. has filed a definitive proxy statement with the SEC, related to its upcoming shareholder meeting.

Carl Icahn and affiliated entities have fully divested their stake in Bausch Health Companies Inc., selling over 34.7 million shares at $9.00 each.

Paulson & Co. Inc. has significantly increased its beneficial ownership in Bausch Health Companies Inc. to 19.1% through recent share purchases.

Paulson & Co. Inc. has significantly increased its beneficial ownership in Bausch Health Companies Inc. to 8.9% through a series of recent common share acquisitions.

Paulson & Co. Inc. has updated its beneficial ownership in Bausch Health Companies Inc. to 7.1% and entered into a new governance agreement with the company, restricting certain activist actions in exchange for board representation commitments.

Carl Icahn's investment entities have entered into a supplemental agreement with Bausch Health Companies Inc., adjusting terms related to board representation and voting rights for their designees.

Activist investor Alex Meruelo has disclosed a nearly 10% beneficial ownership stake in Bausch Health Companies Inc., signaling his intent to join the board and influence strategic decisions to enhance shareholder value.

Nomura Holdings Inc. and its subsidiary, Nomura Global Financial Products, Inc., reported a 4.2% beneficial ownership stake in Bausch Health Companies Inc. as of September 30, 2025.

GoldenTree Asset Management and Steven A. Tananbaum have disclosed a combined beneficial ownership of 9.5% in Bausch Health Companies Inc. common shares.

Nomura Holdings Inc. and its subsidiary, Nomura Global Financial Products, Inc., have disclosed a passive beneficial ownership of 6.3% in Bausch Health Companies Inc.